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| INTRODUC TI ON
For more than a decade, it has been appreciated that MrgX2, a G protein-coupled receptor expressed by human mast cells, 1 is probably responsible for the histamine release evoked by 48/80, a synthetic polymer commonly used as a degranulating agent. However, the clinical relevance of this receptor was uncovered only recently, with conclusive identification of the previously elusive mouse MrgX2 homologue, encoded by Mrgprb2. 2 Mice genetically deleted for Mrgprb2 were resistant to local histamine-like effects upon injection with several agents that cause injection-site reactions in man.
Previous studies highlight the promiscuous nature of MrgX2, which can be activated by many synthetic small-molecules and peptides, including US Food and Drug Administration (FDA)-approved drugs, as well as endogenous antimicrobial peptides and neuropeptides. [2] [3] [4] [5] We sought to investigate whether assets in nonclinical drug development, that cause unexplained histamine-like and/or anaphylactoid effects in animals, interact with MrgX2. Based on our results, we considered whether MrgX2 should be included during assessment of secondary (off-target) pharmacology in the early stages of drug development. 6 Human MrgX2 is encoded by MRGPRX2 (for Mas-related G protein-coupled receptor), a member of a large gene family divided into subclasses A to H, and X. MrgprD, MrgprE, MrgprF, and MrgprG subclasses contain a single gene per mammalian species with high sequence homology, and so are readily identified as an orthologous group. 4 In contrast the MrgprA, MrgprB, and MrgprC subclasses are rodent-specific, and the MRGPRX subclass is absent from rodents. 7 A clue to evolution of these receptors is that the large MrgprA and MrgprB subclasses (with at least 26 members in rat and mouse) and the smaller MRGPRX subclass (4 members in human) lie at syntenic chromosomal loci (containing SAAL1, PTPN5, and ZDHHC13 genes), suggesting a common origin. 8 Human MRGPRX2 and mouse MrgprB2 are orthologous, as defined by common function (they encode receptors responsive to compound 48/80 and cortistatin-14) and expression (in subsets of mast cells), even though their sequence identity is relatively low (52%). Low similarity led to their original classification as nominally separate Mrg subclasses. 2 We now understand that ligand specificity, G-protein signaling, and transcriptional regulation are conserved in MRGPRX2/MrgprB2 despite divergence in overall sequence. A plausible explanation for these features, as well as the differences between rat and mouse loci, is that in rodent this locus has been subject to frequent retrotransposon insertion, resulting in duplicative expansion and coordinate divergence. 2, 7 Families A to C and X may be more appropriately regarded as a single subclass of the Mrg family, since human MrgX1 (encoded by MRGPRX1) similarly shares ligands and patterns of expression in common with mouse A and C receptors. 2 Activation of mast cell MrgX2 triggers dual intracellular signaling cascades attributed to G-proteins of the pertussis-toxin sensitive G ifamily and the calcium mobilizing G q/11 -family. 8 Typically, both pathways are required to mediate the ultimate mast cell responses of degranulation, chemotaxis, and cytokine release. Ligand activation of MrgX2 may be conveniently studied by measuring intracellular calcium release in transfected cultured cells (eg HEK293). This approach relies on either endogenous G-proteins present in the host cells used, or additional co-transfected G-proteins that confer calcium responses, such as G α15 or G α16 . Here, we have used this approach in U2 osteosarcoma (U2OS) and other cells to confirm the ligand profile of mouse MrgX2 (encoded by MrgprB2), 2 and to characterize predicted orthologues of MrgX2 from species relevant to nonclinical drug testing. MrgX2 agonists also induce association of the receptor with β-arrestin, a property used previously to identify the -opioid agonist TAN-67 as an agonist of MrgX2. 5 We used receptor association with β-arrestin as an orthogonal assay to confirm newly described agonists of human MrgX2. Our findings show that MrgX2 is conserved in mammals. We characterize a peptide that caused unexpected anaphylactoid symptoms during development, and show it activates MrgX2. Finally, we show that the antibiotic vancomycin is also a MrgX2 agonist. Vancomycin causes clinical histamine-like effects typified by itching, rash and sometimes headache, dizziness, agitation, fever and even chest pain and breathing difficulties. These symptoms, known as red man syndrome, may be associated with activation of MrgX2. 
| MATERIAL S AND ME THODS

| Compounds & peptides
| BacMam Generation
Genes encoding human MRGPRX1 and MrgX2 orthologues (Table   S3 ) were synthesized at GenScript (China). Receptors or G α16 were cloned into pHTBV1mcs3, a modified version of the pHTBV1 BacMam expression vector 10 using EcoRI and HindIII cloning sites.
Recombinant baculoviruses were generated according to manufacturer's protocols using the Bac-to-Bac system (Invitrogen, UK).
All BacMam stocks were sterility checked, confirmed to be mycoplasma-free, and stored at 4°C in the dark to increase viral stability. 
| Ca 2+ mobilization assays
| ß-arrestin recruitment assay in hMrgX2 ProLink -CHO cells 5000 cells/well (Eurofins Pharma Discovery Services PathHunter ® ;
Cat # 93-0309C2; RRID:CVCL_KY49) seeded with 20 µL AssayComplete Cell Plating 2 reagent into white 384-well plates (Corning) were incubated overnight (37°C/ 5% CO 2 ). Test agents were serially diluted in DMSO, added to OptiMEM/0.1% BSA (to 5x final), and 5 µL incubated with cells (90 minutes at 37°C, then 30 minutes at room temperature). Luminescence was detected after addition of 12.5 µL PathHunter ® Detection reagent (Cat # 93-0001; room temperature; 2 hours) using an Envision platereader (Perkin Elmer). 11
| Data Analysis
Data were analysed in GraphPad PRISM 6 as maximum-minimum values normalized against the background average. pEC 50 values were determined using a four-parameter curve fitting equation, and statistical comparisons were performed using unpaired t-test with Welch's correction (*P < .05; **P < .01).
| Assessment of intravenous pharmacokinetics
Animal studies were ethically reviewed and carried out in accord- 
| RE SULTS
| A pan-mammalian family of MrgX2 receptors
We investigated whether inadvertent activation of mast cells via their MrgX2 receptor could be the cause of histamine-like and/or anaphylactoid symptoms, where observed in the past during preclinical in vivo testing for certain drugs in development. Typically, species affected by such symptoms are rat, dog and occasionally minipig or nonhuman primate. We therefore sought to profile putative MrgX2 agonists across orthologous receptors spanning a range of mammalian species.
We first identified a cell host suitable for expression of MrgX2.
Human U2OS cells released intracellular calcium upon treatment
with histamine which activates an endogenously-expressed receptor ( Figure 1B ). No U2OS calcium response was detected upon treatment with the MrgX2 agonists cortistatin-14, 48/80, BAM22P, or icatibant. U2OS cells therefore were presumed to lack endogenous MrgX2 ( Figure 1A ).
Next, we introduced human MrgX2 (hMrgX2) by using a modified baculovirus, BacMam, that can transduce exogenous genes and express them under control of a mammalian promoter. Titration of hMrgX2 BacMam up to a multiplicity of infection (MOI) of 100 conferred calcium responses to cortistatin-14 and 48/80 ( Figure 1C&D ).
Half-maximal effects at different MOI ranged from pEC50 = 6.1 to 6.5 for cortistatin-14, and pEC50 = 5.4 to 5.6 for 48/80. These potencies were lower than reported values, 2 therefore we included BacMam viruses encoding G α16 to enhance coupling to calcium-mobilization pathways. G α16 potentiated hMrgX2 responses to 48/80, and resulting half-maximal effects were consistent with reported values (pEC50 = 5.9 ± 0.18; n = 3 for 48/80). U2OS cells transduced with G α16 in the absence of hMrgX2 were unresponsive ( Figure 2A ).
We also expressed human MrgX1 (hMrgX1), using BAM-22P and BAM 8-22 as reference agonists. hMrgX1 agonist responses were also potentiated by co-transduction with G α16 . BAM-22P activated hMrgX1-G α16 and hMrgX2-G α16 cells at similar potencies (data not shown), whereas BAM 8-22 had a higher potency at hMrgX1-G α16 cells, as expected ( Figure 2B ). 48/80 was specific for hMrgX2, since no calcium responses of hMrgX1-G α16 cells were observed (data not shown).
Mouse MrgX2 (mMrgX2) is the product of the Mrgprb2 gene. 2 
We observed that transduction of U2OS cells with Mrgprb2
BacMam at MOI comparable to those used for hMrgX2 was detrimental to health of cells. This effect was apparent morphologically as rounded cells and by marked reduction in calcium release in response to histamine (data not shown). Reducing the MOI of Mrgprb2 restored potency of endogenous histamine responses and conferred calcium responses to 48/80 at potencies consistent with previously reported values ( Figure 2C ). 2 
Genes encoding
MrgX2 orthologues in other species have not yet been described.
The human chromosome 11 region that contains genes encoding
MrgX1 and MrgX2 is syntenic to regions of rat chromosome 1 and mouse chromosome 7. In rodent, these loci have undergone gene duplication and at least eight candidate rat orthologues exhibit homology to MrgX2. 12 Unambiguous prediction of the rat MrgX2 orthologue based on sequence similarity to mMrgX2 and hMrgX2 was not possible (see Supplementary Methods), therefore we expressed the four most likely candidate genes (Mrgprx1, Mrgprx2, Mrgprx2l, and Mrgprb3) in U2OS cells. Only Mrgprb3 conferred a response to 48/80 and cortistatin-14 ( Figure 2D and Figure   S1 ). Based on this and other evidence 8 we ascribed Mrgprb3 to encode rat MrgX2 protein (rMrgX2) and to be orthologous to human MRGPRX2 and mouse Mrgprb2. We attempted to express mMrgX2 and rMrgX2 under the same conditions as hMrgX2, ie Unambiguous predictions of MrgX2 orthologue-encoding genes were made in the genomic sequence of canine (beagle), porcine (minipig and pig) and primate (Rhesus and cynomolgus monkey) species (see Table S3 for gene identities). Orthologous receptors were termed beMrgX2 (beagle dog), mpMrgX2 (minipig), pMrgX2 (pig), rhMrgX2 (Rhesus monkey), and cyMrgX2 (cynomolgus monkey). (n = 3), rMrgX2: 5.4 ± 0.1 (n = 4), beMrgX2: 6.1 ± 0.08 (n = 3), mp-MrgX2: 5.9 ± 0.10 (n = 3), pMrgX2: 5.9 (n = 1), rhMrgX2: 6.7 (n = 1), cyMrgX2: 6.1 (n = 1) (mean pEC 50 ± SEM, based on a notional molecular weight for 48/80 of 500).
| Cell-penetrant peptides with MrgX2 agonist activity
GSK3212448 (peptide 1) and peptide 4 are stabilized peptides with related sequences (Table S1 ). Both caused unexpected histamine-like symptoms in vivo. These peptides were designed to penetrate cells and disrupt the interaction between EZH2 (enhancer of zeste homolog 2) and EED (embryonic ectoderm development), which are components of the epigenetic regulator PRC2 (Polycomb repressive complex 2). In common with similar published peptides that reduce trimethylation activity of PRC2 at histone H3 K 27 , 13 GSK3212448 and peptide 4 bind EED with high affinity (IC 50 = 20 nmol/L, for GSK3212448). Predicted net charge at pH 7 is +5 for GSK3212448 and +3 for peptide 4. To determine pharmacokinetic properties of the peptides, rats were treated intravenously by bolus dose (5 mg/kg) given over approximately 1 minute. Both peptides were tested as part of the same study. For each peptide, the first dosed animal showed potential signs of anaphylaxis, with blue-colored extremities, gasping, and limpness. Symptoms were observed within 3 minutes for peptide 4 and within 2 minutes for GSK3212448; animals were immediately euthanized by cervical dislocation and death was confirmed. No further rats were dosed. Subsequently, we found GSK3212448 to activate hMrgX2. Preliminary data suggested that GSK3212448 could activate hMrgX2-G α16 -U2OS but not G α16 -U2OS cells (not shown). Using CHO-K1 cells stably expressing C-terminally tagged hMrgX2 (hMrgX2 ProLink -CHO), GSK3212448 caused robust, concentration-dependent calcium responses (pEC 50 = 6.1 ± 0.14 (n = 4); Figure 3A ). hMrgX2 ProLink -CHO cells also express a tagged version of β-arrestin 2 , allowing measurement of agonist-induced association between receptor and β-arrestin 2 . GSK3212448 induced association of hMrgX2 with β-arrestin 2 (pEC 50 = 6.0 ± 0.10 (n = 4); Figure 3B ). In U2OS cells, GSK3212448 activated the rat orthologue (rMrgX2) 18-fold more potently than the reference agonist 48/80 (pEC 50 = 6.5 ± 0.21 and 5.2 ± 0.17 (both n = 4) for GSK3212448 and 48/80, respectively; Figure 3C ). GSK3212448 also activated beMrgX2, mpMrgX2, and pMrgX2 (data not shown). In the pharmacokinetic study, GSK3212448 was injected at a concentration > 1000-fold greater than its pEC 50 at rMrgX2, potentially sufficient to cause systemic degranulation of connectivetissue mast cells after dose dilution into circulation. Peptide 4 also activates hMrgX2 (pEC 50 = 5.4 ± 0.05 (n = 4; calcium) and 5.2 ± 0.06 (n = 3; β-arrestin 2 ); Table S1 ). These findings offer a mechanistic explanation of anaphylactoid symptoms and illustrate how prior knowledge of MrgX2 activity and agonist profile across species orthologues could mitigate risk of anaphylactoid symptoms by enabling a knowledge-based choice of species and dosing regimen.
| Diverse basic peptides activate MrgX2
We next investigated the structure-activity relationship (SAR) of peptides for agonism of MrgX2. Like GSK3212448, many known MrgX2 peptide agonists have net basicity. Cell penetrating peptides are often also basic, since positive charge can aid cell penetration, with little additional requirement for specific amino acids or sequence motifs. 14 pEC 50 = 5.3 ± 0.05, n = 4 (β-arrestin 2 association)). To illustrate that MrgX2 activation is not sequence-specific, we also tested a peptide containing only arginine residues (polyarginine; Ac-Arg 9 -amide),
showing that basic residues alone are sufficient to activate MrgX2 (pEC 50 = 6.9 ± 0.10, n = 4 (calcium mobilization); pEC 50 = 5.8 ± 0.10, n = 4 (β-arrestin 2 association)).
Next, we reviewed literature reports of peptides tested in recombinant hMrgX2 calcium and/or β-arrestin assays. These peptides have diverse origins and include various hormones, fragments of albumin isolated from blood plasma, anti-bacterial peptides, and pharmaceutical agents. A compilation of agonist pEC 50 values from these reports is presented in Table S2 . In all cases, the relationship between net charge and hMrgX2 agonist activity described above holds. Figure 4 shows a scatter plot of hMrgX2 potency vs predicted charge at neutral pH for peptides tested in this study and literature peptides, including also the peptidomimetic polymer 48/80 (data from the combination of Tables S1 and S2). In summary, peptides of charge ≥+3 commonly activate MrgX2, whereas peptides of charge ≤ 0 rarely activate MrgX2. This relationship is consistent with the numerous peptide mast cell degranulating agents described in the literature.
| Diverse basic small-molecules activate MrgX2
We investigated whether MrgX2 was similarly promiscuous toward activation by small molecules. We tested 368 structurally diverse drug-like compounds. Roughly one-third of compounds tested (137) induced concentration-dependent calcium mobilization in HEK293-MSRII cells expressing hMrgX2 plus G α16 , measured using FLIPR. To distinguish hMrgX2-selective agonists from compounds acting at other receptors endogenously expressed in HEK293-MSRII cells, active compounds were retested using cells transduced either with hMrgX2 plus G α16 or G α16 alone (both tested in duplicate). Sixtyeight compounds (≈18% of the initial set) exhibited hMrgX2-specific activation with pEC50 > 4.5 (criteria for defining hits are described in Figure 5A,B) . However, pEC 50 did not correlate with predicted pK B ( Figure 5C ).
F I G U R E 4
Relationship between hMrgX2 agonist potency and charge amongst peptides. Forty-six peptides are included, plus compound 48/80 whose polymeric structure is analogous to a basic peptide, with a repeating unit that presents a basic secondary amine side-chain (48/80 is given a notional net charge at pH 7.0 of 4.5 units, here). hMrgX2 agonist data were either generated within this study (Table S1 , which also shows experimental replication) or are extracted from literature reports (Table S2 ) and show pEC 50 values (mean ± SD for data generated within this study) for calcium mobilization, or, where no pEC 50 for calcium mobilization was available, for β-arrestin association assays termed red man syndrome. 15 Red man syndrome has been linked to vancomycin treatment for more than 30 years, 16 and may be caused by oral, intraperitoneal, or intravenous routes of administration. 17, 18 Vancomycin is a glycopeptide with several exposed basic centers, reminiscent of GSK3212448 and other peptides shown here to activate hMrgX2. In hMrgX2-transfected U2OS cells, vancomycin elicited calcium responses with similar efficacy to 48/80 (pEC 50 = 4.4 ± 0.04 and E max = 87 ± 8% (n = 2) on hMrgX2-G α16 -U2OS cells; Figure 6 ). Negligible calcium responses were observed in untransfected U2OS parent cells challenged with either vancomycin or 48/80 whereas robust U2OS calcium responses were evoked by histamine (data not shown), consistent with activation of MrgX2 by vancomycin. Activation of hMrgX2 ProLink -CHO cells did not reach F I G U R E 5 Frequency of MrgX2-active agonists amongst drug-like small molecules. Structurally diverse drug-like compounds (structures not disclosed) were tested for hMrgX2 agonism using HEK293-MSRII cells. Bargraphs show (A) number and (B) proportion of neutral, acidic or basic compounds in the 368-compound starting set and amongst MrgX2-active hits. Calcium mobilization assays were performed in Poly-D-lysine coated 384-well plates (Greiner Bio-One), and buffer contained 2.5 mmol/L probenecid, 2 µmol/L Fluo-4, and 500 µmol/L Brilliant Black (otherwise as described in Methods). Test compounds were serially diluted in DMSO, transferred to 384-well polypropylene V-bottom plates (Greiner Bio-One) using an ECHO 555 liquid handler (Labcyte), then further diluted into assay buffer supplemented with 0.03% Pluronic acid (Sigma) and 0.03% CHAPS (Sigma), before test in duplicate. Curve-fitting (Activitybase XE, IDBS) was performed where fold increase over basal was ≥ 1.3. Cortistatin-14 and carbachol (to activate endogenous muscarinic receptor) were included to ensure consistency between plates. MrgX2-active hits were defined as having pEC 50 > 4.5 at hMrgX2, >0.5 log unit greater pEC 50 at hMrgX2-G α16 compared to cells transfected with G α16 alone, and > 50% efficacy compared to Cortistatin-14. (C) Correlation of basicity (calculated pK B ) with hMrgX2 mean pEC 50 (n = 2) for 68 hMrgX2-active hits. Acid and base properties were categorized using in silico Chemaxon tools maximal effect and curve-fitting was not attempted. However, vancomycin (0.3mM) caused approximately 50% of maximal effect of cortistatin-14 (Fig. S5 ). Potency of vancomycin to activate hMrgX2 is low compared with other MrgX2 agonists associated with pseudo-allergic reactions. However, trough (lowest) free serum concentrations in vancomycin-treated patients are ≈5 ± 2 µmol/L (13.6 ± 5.9 mg/L; 50% protein binding) and C max may exceed 30 µmol/L. 19 Therefore, vancomycin activity at hMrgX2 may be sufficient to cause red man syndrome and other histamine-like or pseudo-allergic reactions at clinical exposures. Vancomycin induces degranulation of isolated rat mast cells, 20 so we tested whether rodent MrgX2 was also sensitive to the drug. Vancomycin-evoked calcium release in mMrgX2and rMrgX2-expressing U2OS cells did not reach maximal effect at 1mM ( Figure 6 ) consistent with the high concentrations of vancomycin required for full degranulation of rat mast cells (4.55 mg/ml or 3 mmol/L). 20 Finally, we showed that vancomycin behaved as a full or near-full agonist at beMrgX2 and mpMrgX2 (pEC 50 = 4.6 ± 0.2 and E max = 97 ± 12% (n = 3) at beMrgX2 and 3.8 ± 0.07 and E max = 84 ± 13% (n = 3) at mpMrgX2; Figure 6 ). In summary, activation of MrgX2 by vancomycin is sufficient to mediate mast cell degranulation and the clinical adverse reactions termed red man syndrome. By identifying mouse MrgX2, the authors showed conclusively that medicines causing anaphylactoid reactions, such as injection site reactions, mediated these effects via agonism of MrgX2. Reactions like those seen in human could be replicated in wild-type mice but were absent in animals genetically deleted for MrgX2. 2 We set out to show that MrgX2 orthologues occur not only in human and mouse but also in other mammalian species corresponding to those commonly used in preclinical studies: rat, dog, minipig, and nonhuman primate. Other authors have termed MrgX2 "primate-exclusive", 3 but we were able to unambiguously predict candidate MrgX2 orthologues of nonprimate species from publicly-available genomic sequence. Expression of candidate MrgX2 orthologues in U2OS cells conferred calcium responses to the archetypal MrgX2 ligand, 48/80. In rat, no single likely orthologue could be predicted amongst the multiple homologues that are present in the rat syntenic locus due to gene duplication and divergence events in the rodent lineage. 7 Instead, four potential orthologues were tested. Only one rat gene, Mrgprb3, conferred calcium responses to compound 48/80 upon transfection into U2OS cells.
| Activation of MrgX2 by vancomycin as a potential cause of Red Man Syndrome
| D ISCUSS I ON
We therefore ascribed Mrgprb3 to encode rat MrgX2 (rMrgX2) and F I G U R E 6 Vancomycin activates MrgX2. Calcium mobilization assays were performed as described in Figure  2 , expressing MrgX2 orthologues in U2OS cells (beMrgX2, pMrgX2, and mpMrgX2 were expressed truncated of their elongated N-terminal domains, and hMrgX2 was expressed in combination with G α16 ). Data were normalized to the effect of 48/80 (100%). Representative experiments are shown; each data point is mean ± SD of 3-16 determinations. For experimental replication, see Results to be orthologous to human Mrgprx2 and mouse Mrgprb2 (encoding hMrgX2 and mMrgX2 respectively). Findings reported by other authors support this. 8 Additional G α subunits substantially reduced responses of rat and mouse MrgX2. Incompatibility with G α16 may be specific to the U2OS cells used here, because agonist responses were observed for mMrgX2 (Mrgrpb2) expressed in HEK293 cells in combination with G α15 . 2 Further studies will be required to understand the underlying cause, but our data establish a key difference between rodent and whereas several other Mrg-homologues were expressed at only low levels. 8 Here, we have not examined mast cells expression, but rather we show an association of a novel MrgX2 agonist, peptide GSK3212448, with systemic anaphylactoid symptoms in rat. We have also identified small-molecule development drugs for which histamine-like symptoms had been observed during preclinical in vivo studies, using text-mining searches of study reports or anecdotal accounts. These agents also activate MrgX2 across species and will be the subject of a separate report. We speculate that species-specific histamine-like effects of development drugs might result, at least in part, from greater potency at specific MrgX2 orthologues. This would be unsurprising given the relatively low sequence homology amongst orthologues (substance P is 360-fold less potent at mouse than human, whereas icatibant is only twofold less potent at mouse 2 ). Strikingly, GSK3212448 had greater potency at rMrgX2 than hMrgX2, and is the most potent agonist of rMrgX2 yet observed.
We tested further peptides and small-molecules to understand the SAR of MrgX2. Known peptides with MrgX2 agonist activity are remarkably numerous, and include several ligands of other GPCRs, such as Substance P and cortistatin-14. Our findings show a lack of sequence-specificity amongst active MrgX2 agonist peptides, which instead have in common net positive charge at pH7.0. Polyarginine (Ac-Arg 9 -amide) was close to equipotent to cortistatin-14 (Table   S1 ), illustrating that basic amino acids alone are sufficient to activate MrgX2 and that hydrophobic amino acids or other sequence The possibility that endogenously occurring peptides and proteins represent physiologically-relevant ligands for MrgX2 has been explored in depth for cortistatin-14, 21 Substance P, 22 endorphins, 3 β-defensins, 23 and others. 24 However, our finding that activation of MrgX2 may not be sequence-specific but is instead driven by charge raises the possibility that no physiologically relevant cognate endogenous MrgX2 agonist exists. Activation of MrgX2 by peptides such as Substance P and cortistatin-14 at concentrations in the range 100-1000 nmol/L may be coincidental due to their high basic charge. MrgX2 may operate as a sentinel, analogous to pathogen pattern-sensors such as FPR receptors, activating elements of the innate immune system in response to local pathogen-derived features. FPR1 and FPR2 are expressed on leucocytes and respond to N-formyl motifs characteristic of bacteria, or to other bacterially-derived peptides. 25 By analogy, MrgX2 enables mast cells to respond to pathogen-derived basic peptides including those that have cell-penetrating properties. As well as the cell-penetrant fragment of HIV TAT protein, TAT (49-60), shown here to activate hMrgX2, S aureus -toxin and competence-stimulating peptide (CSP)-1 secreted by Gram-positive bacteria also activate hMrgX2. 26, 27 In this way MrgX2 may detect both viral and bacterial xenobiotic features.
The promiscuous nature of MrgX2 is also reflected in our finding of frequent weak agonist activity amongst drug-like small molecules (≈18% of compounds tested). As with peptides, many novel MrgX2 agonists were basic. Based on our understanding of MrgX2 SAR, we hypothesized that vancomycin might also activate MrgX2, and confirmed this through testing. Vancomycin is a basic glycopeptide that achieves high exposures in treated patients, and is associated with histamine-like symptoms termed red-man syndrome. 15 During preparation of this manuscript, Azimi et al (2017) also showed vancomycin to activate hMrgX2, inducing calcium mobilization in HEK293 cells expressing hMrgX2 and degranulation of LAD-2 mast cells. Both effects could be blocked by an MrgX2 antagonist. 26 We showed vancomycin to activate all mammalian MrgX2 orthologues tested. It is somewhat surprising that no histamine-like symptoms were observed in literature reports of vancomycin administration to dog (free C max ≈35 µmol/L; ≈100 µg/ml, assuming 50% protein binding) 28 and minipig (free C max ≈23 µmol/L; 34 µg/mL). 29 Possibly these studies did not cause sufficient (or sufficiently rapid) exposure to vancomycin to induce the symptoms. Other antibiotics have also been associated with red man syndrome, including ciprofloxacin, 15 which has also been shown to activate MrgX2. 2 We speculate that agents and/ or dosing regimens that lead to high C max and fast onset of C max (rapid, high exposure) in combination with MrgX2 agonism, would be the most liable to result in systemic anaphylactoid symptoms.
Oral vancomycin can also cause symptoms. 30 Red man syndrome is often associated with the first dose of vancomycin and can by mitigated or avoided by reduced infusion rates, whereas combining vancomycin with other antibiotics, contrast dyes or opioid analgesics can amplify red man syndrome. 15 We speculate that slower onset of C max desensitizes MrgX2 to limit histamine release, whereas combination of vancomycin with other potential MrgX2 agonists could have additive effects. Basic peptides as therapeutics may be particularly liable for MrgX2-mediated histamine-like reactions, though subcutaneous and intramuscular administration may lead to local injection-site reactions, 2 rather than the systemic effects we observed with GSK3212448 in rat.
In conclusion, our data extend the association between agonism of the mast cell MrgX2 receptor and histamine-like anaphylactoid effects into both clinical and preclinical drug-development settings. 
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